Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Prague – page 69

1 218 clinical trials in Prague, Czechia across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Prague at a glance
1 218
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

1 218 trials in Prague

Open in trial search

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Opthea Limited

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Stopping Nilotinib, Imatinib, and Dasatinib in Patients with Chronic Myeloid Leukemia in Deep Remission

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Masarykova Univerzita

Study of Disulfiram and Copper for Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Disulfiram
  • Sponsor:Univerzita Palackeho V Olomouci

Fabry's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Pegunigalsidase Alfa for Adults with Fabry Disease

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Pegunigalsidase Alfa
  • Sponsor:Chiesi Farmaceutici S.p.A.

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Study on Long-Term Safety and Effects of Pegcetacoplan for Patients with Geographic Atrophy from Age-Related Macular Degeneration

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Acute myeloid leukaemia+2

Not recruiting

Study on Continued Treatment with Sabatolimab for Adults with High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Unfit for Chemotherapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Novartis Pharma AG

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Prague

What the registry says about research in the country

01 Neoplasms and Oncology

Clinical trial activity in Praha includes research in advanced melanoma and diffuse large B-cell lymphoma, with a strong focus on improving cancer control and extending survival.

  • Advanced melanoma
  • Previously untreated diffuse large B-cell lymphoma
  • Testing new treatment combinations
  • Evaluating survival outcomes and disease progression

These studies are designed to refine how immunotherapy and other cancer treatments perform in everyday clinical care.

02 Cardiovascular Diseases

Research in cardiovascular diseases is centered on reducing major heart and vascular events, with trials looking at hypertension, atherosclerotic cardiovascular disease, and heart failure prevention.

  • Hypertension
  • Atherosclerotic cardiovascular disease
  • Prevention of heart failure
  • Lowering the risk of stroke and other vascular complications

Several studies aim to improve treatment effectiveness for patients at elevated cardiovascular risk.

03 Respiratory Tract Diseases

Trials in the respiratory field focus on better symptom control and fewer flare-ups in chronic obstructive pulmonary disease, alongside ongoing work in infection-related lung illness.

  • Chronic obstructive pulmonary disease
  • Covid-19 in people at high risk of severe illness
  • Testing new antiviral and anti-inflammatory approaches
  • Reducing exacerbations and severe outcomes

These studies support more effective care for both chronic and acute respiratory conditions.

04 Skin and Connective Tissue Diseases

Dermatology research in Czechia includes several inflammatory skin disorders, with studies targeting itch, lesion control, and long-term disease management.

  • Atopic dermatitis
  • Moderate to severe plaque psoriasis
  • Hidradenitis suppurativa
  • Neurodermatitis and lichen simplex chronicus

The goal is to evaluate new therapies that may ease symptoms and improve quality of life.

05 Immune System Diseases

Studies in immune-mediated disease are exploring treatments that can calm abnormal inflammation while maintaining safety and tolerability.

  • Psoriatic arthritis
  • Atopic dermatitis
  • Psoriasis-related inflammatory conditions
  • Assessing immune-targeted therapy effectiveness

These trials aim to improve control of chronic immune-driven disease burden.

06 Nervous System Diseases

Neurology-related research focuses on agitation in Alzheimer's disease dementia, with efforts to better manage behavioral symptoms that affect patients and caregivers.

  • Agitation in Alzheimer's disease dementia
  • Symptom relief and behavioral improvement
  • Evaluating new therapeutic options

These studies may help support more practical care for people living with dementia.

07 Nutritional and Metabolic Diseases

Metabolic research in Praha includes trials for overweight, obesity, and related conditions, often linked with cardiovascular risk.

  • Overweight and obesity
  • Hypertension with obesity
  • Type 2 diabetes-related weight management
  • Supporting weight loss and cardiometabolic health

These studies are testing approaches that may help reduce long-term health risks tied to excess weight.

08 Virus Diseases

In the area of virus diseases, research is centered on improving treatment options for people with COVID-19 who are at higher risk of becoming seriously ill.

  • COVID-19 at high risk of progression
  • Reducing illness severity
  • Testing antiviral treatment effectiveness

The main aim is to help prevent worsening disease and support faster recovery.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.